Bessemer Group’s Denali Therapeutics DNLI Stock Holding History

Bessemer Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-110	Closed	-$2K	–	2504
2024 Q4	$2K	Hold	110	–	–	﹤0.01%	2200
2024 Q3	$3K	Buy	+110	New	+$2.73K	﹤0.01%	2079

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bessemer Group's DNLI Position: Q1 2025 in Review

Bessemer Group sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 110 shares — an estimated $2K sold.

Bessemer Group first reported a position in DNLI in Q3 2024 and held it in 2 quarters. The position peaked at $3K in Q3 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Bessemer Group reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Bessemer Group sold 110 Denali Therapeutics shares in Q1 2025, an estimated $2K.
Bessemer Group first reported a position in Denali Therapeutics in Q3 2024 and held it in 2 quarters.
Bessemer Group's Denali Therapeutics position peaked at $3K in Q3 2024.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Bessemer Group's 13F filing for Q1 2025, filed 23 Apr 2025.